newsfilter
← Latest News
GlobeNewswire·

Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx's TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting

RNXT
  • RenovoRx announced clinical data from Moffitt Cancer Center presented at the 2026 Society of Interventional Radiology Annual Scientific Meeting regarding Trans-Arterial Micro-Perfusion (TAMP) therapy for locally advanced pancreatic cancer.
  • The study demonstrated that TAMP offers a promising approach for localized gemcitabine delivery with reduced systemic toxicity compared to intravenous chemotherapy.
  • Metabolic imaging via FDG PET/CT showed notable reductions in tumor activity & FDG avidity, suggesting treatment response even when anatomical tumor size changes were minimal.
  • Patients received eight cycles of intra-arterial chemotherapy over two months using the RenovoCath device to enable the TAMP platform.
  • Dr. Mustafa Al-Roubaie highlighted that TAMP increases local drug concentration near the tumor while minimizing systemic exposure, addressing the poor vascularity of solid tumors.
  • RenovoRx generated approximately $1.1 million in RenovoCath sales during its first full year of commercialization & is expanding orders with National Cancer Institute-designated centers.
  • The company is evaluating its drug-device combination candidate (intra-arterial gemcitabine via RenovoCath, known as IAG) in the ongoing Phase III TIGeR-PaC clinical trial.
  • IAG has received Orphan Drug Designation for pancreatic cancer & bile duct cancer, granting seven years of market exclusivity upon FDA approval.
  • Forward-looking statements in the release note risks regarding clinical trial outcomes, regulatory approvals, commercialization success, & financial requirements.